Rubino Christopher M, Ambrose Paul, Cirincione Brenda, Arguedas Adriano, Sher Lawrence, Lopez Eduardo, Sáez-Llorens Xavier, Grasela Dennis M
Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206, USA.
Diagn Microbiol Infect Dis. 2007 Sep;59(1):67-74. doi: 10.1016/j.diagmicrobio.2007.04.015.
Gatifloxacin is a 4th-generation fluoroquinolone previously under investigation for the treatment of otitis media in infants and children. These analyses were designed to evaluate the extent of drug exposure relative to adult populations and to examine the relationship between drug exposure and response to therapy in children with recurrent otitis media or early treatment failures of acute otitis media. The patient population included 187 patients from an open-label, multicenter, noncomparative study using gatifloxacin 10 mg/kg once daily. Gatifloxacin exposure was estimated using a single steady-state blood sample in conjunction with a pharmacostatistical model developed using a separate pediatric data set. Gatifloxacin exposure was equivalent to that in adults given 400 mg daily. Of the 41 patients who had Streptococcus pneumoniae from middle ear culture, there were only 3 bacteriologic failures; there was no relationship between plasma fu AUC(0-24):MIC ratio and outcome. In conclusion, population pharmacokinetic/pharmacodynamic methods allowed estimation of drug exposure using one sample per patient.
